Coeliac Disease Case-Control Study: Has the Time Come to Explore beyond Patients at Risk?

• Published in: Nutrients 2023-03, Vol.15 (5), p.1267
• Main Authors: Castillejo, Gemma, Ochoa-Sangrador, Carlos, Pérez-Solís, David, Cilleruelo, Maria Luz, Donat, Ester, García-Burriel, Jose Ignacio, Sánchez-Valverde, Félix, Garcia-Calatayud, Salvador, Eizaguirre, Francisco Javier, Martinez-Ojinaga, Eva, Barros, Patricia, Leis, Rosaura, Salazar, Jose Carlos, Barrio, Josefa, Peña-Quintana, Luis, Luque, Verónica, Polanco, Isabel, Ribes, Carmen, Roman, Enriqueta
• Format: Article
• Language: English
• Subjects: Abdomen; Age; Antibodies; Asymptomatic; Autoantibodies; Autoimmune diseases; Biopsy; Blood tests; Case-Control Studies; Celiac disease; Celiac Disease - diagnosis; Child; Children; coeliac disease; Comparative analysis; Complications; Complications and side effects; Development and progression; Diagnosis; Disease control; Families & family life; Family medical history; Gastroenterology; general practice; Hepatology; Humans; Immunoglobulin A; Mass Screening; Nutrition; Patients; pediatric gastroenterology; Pediatric research; Pediatrics; Questionnaires; Risk factors; screening; Serology; Signs and symptoms; Symptomatology; Transglutaminases
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu15051267

The worldwide prevalence of asymptomatic coeliac disease (CD) is increasing, which is in part due to the routine screening of children with risk factors. Both symptomatic and asymptomatic patients with CD are at risk of long-term complications. The objective of this study was to compare the clinical characteristics of asymptomatic and symptomatic children at the time of CD diagnosis. A case-control study was conducted using data from a cohort of 4838 CD patients recruited from 73 centers across Spain between 2011 and 2017. A total of 468 asymptomatic patients (cases) were selected and matched by age and sex with 468 symptomatic patients (controls). Clinical data, including any reported symptoms, as well as serologic, genetic, and histopathologic data were collected. No significant differences were found between the two groups in most clinical variables, nor in the degree of intestinal lesion. However, the asymptomatic patients were taller (height z-score -0.12 (1.06) vs. -0.45 (1.19), < 0.001) and were less likely to have anti transglutaminase IgA antibodies ≥ 10 times the upper normal limit (66.2% vs. 758.4%, = 0.002). Among the 37.1% of asymptomatic patients who were not screened for CD due to the absence of risk factors, only 34% were truly asymptomatic, while the remaining 66% reported non-specific CD-related symptoms. Therefore, expanding CD screening to any child who undergoes a blood test could reduce the burden of care for some children, as many of those considered asymptomatic reported non-specific CD-related symptoms.